Evaluation of the role of UGT1A1 genotype testing in colorectal cancer patients administered irinotecan and the occurence of grade 3 and 4 neutropenia.

被引：2
|
作者：
Patel, Sushma M.
Chan, Jim
Hui, Rita L.
Spence, Michele M.
机构：
[1] Kaiser Permanente, Oakland, CA USA
[2] Kaiser Permanente, Downey, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.412
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Han, Fei-fei
    Guo, Chang-long
    Yu, Dan
    Zhu, Jin
    Gong, Li-li
    Li, Guang-run
    Lv, Ya-li
    Liu, He
    An, Guang-yu
    Liu, Li-hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 779 - 788
  • [22] Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
    Thu Nguyen, Cuc Thi
    Minh Thuy, Nguyen Thi
    Huong, Phung Thanh
    PHARMACOGENOMICS, 2024, 25 (10-11) : 469 - 477
  • [23] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165
  • [24] Impact of UGT1A1 genotype and irinotecan exposure on outcomes in Japanese patients with advanced colorectal cancer treated by irinotecan-based regimens
    Ichikawa, W.
    Uehara, K.
    Minamimura, K.
    Tanaka, C.
    Sadahiro, S.
    Shinozaki, K.
    Fukumoto, K.
    Takii, Y.
    Otsuji, T.
    Kambara, T.
    Gamoh, M.
    Morita, S.
    Ando, Y.
    Arai, M.
    Sugihara, M.
    Sugiyama, T.
    Ohashi, Y.
    Sakata, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S362 - S362
  • [25] Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
    Satoh, Taroh
    Ura, Takashi
    Yamada, Yasuhide
    Yamazaki, Kentaro
    Tsujinaka, Toshimasa
    Munakata, Masaki
    Nishina, Tomohiro
    Okamura, Shu
    Esaki, Taito
    Sasaki, Yasutsuna
    Koizumi, Wasaburo
    Kakeji, Yoshihiro
    Ishizuka, Naoki
    Hyodo, Ichinosuke
    Sakata, Yuh
    CANCER SCIENCE, 2011, 102 (10) : 1868 - 1873
  • [26] Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab
    Gupta, Bhavna
    LeVea, Charles
    Litwin, Alan
    Fakih, Marwan G.
    CLINICAL COLORECTAL CANCER, 2007, 6 (06) : 447 - 449
  • [27] UGT1A1*28 genotype and irinotecan dose adaptation in patients with metastatic colorectal cancer (MCRC) - A dutch colorectal cancer group (DCCG) study
    Kweekel, Dina M.
    Gelderblom, Hans
    van der Straaten, Tahar
    Punt, Cornelis J.
    Guchelaar, Henk-Jan
    ANNALS OF ONCOLOGY, 2006, 17 : 257 - 257
  • [28] UGT1A1 promoter genotype and toxicity in patients with advanced colorectal cancer treated with irinotecan-containing chemotherapy.
    Chiara, S
    Serra, M
    Marroni, P
    Lastraioli, S
    Ponzanelli, A
    Tomasello, L
    Leonardi, F
    Franzini, E
    Paganuzzi, M
    Notaro, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 139S - 139S
  • [29] Re:: UGT1A1*28 genotype and irinotecan-induced neutropenia:: Dose matters -: Reply
    Hoskins, Janelle M.
    McLeod, Howard L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (03)
  • [30] Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer
    Iwasa, Satoru
    Muro, Kei
    Morita, Satoshi
    Park, Young Suk
    Nakamura, Masato
    Kotaka, Masahito
    Nishina, Tomohiro
    Matsuoka, Hiroshi
    Ahn, Joong Bae
    Lee, Keun-Wook
    Hong, Yong Sang
    Han, Sae Won
    Cho, Sang-Hee
    Zhang, Dong-Sheng
    Fang, Wei-Jia
    Bai, Li
    Yuan, Xiang-Lin
    Yuan, Ying
    Yamada, Yasuhide
    Sakamoto, Junichi
    Kim, Tae Won
    CANCER SCIENCE, 2021, 112 (11) : 4669 - 4678
12345